Key result
A lower blood pressure treatment target (<130/80 mmHg) may delay renal disease progression only in nondiabetic CKD patients with proteinuria >300 mg/day, with no clear cardiovascular benefit.
Why the study?
Does a lower blood pressure treatment target (<130/80 mmHg) prevent progression of CKD and cardiovascular events in patients with nondiabetic chronic kidney disease?
Does a lower blood pressure treatment target (<130/80 mmHg) prevent progression of CKD and cardiovascular events in patients with nondiabetic chronic kidney disease?
A lower blood pressure target of <130/80 mmHg may delay renal disease progression in nondiabetic CKD patients with proteinuria, but standard targets (<140/90 mmHg) remain appropriate for those without.
Lower BP targets may preserve renal function in proteinuric nondiabetic CKD; leaves open optimal goals without proteinuria.
PURPOSE OF REVIEW: To summarize the available evidence on whether a lower blood pressure (BP) treatment target can ameliorate the progression of nondiabetic chronic kidney disease (CKD), and prevent cardiovascular events in CKD patients. RECENT FINDINGS: The three prospective, randomized controlled trials which addressed the question of progression of CKD suggest that a lower BP treatment goal (<130/80 mmHg) may lead to better preservation of renal function, but only in those patients with proteinuria of more than 300 mg/day. However, the evidence is not conclusive. We are not aware of adequately powered, randomized trials that have assessed the efficacy of lower target BP levels for the prevention of cardiovascular events specifically in nondiabetic CKD patients. The available circumstantial evidence (e.g., subgroup analyses of CKD patients in cardiovascular trials) fails to reveal a clear benefit of a lower BP goal. SUMMARY: There is currently no convincing evidence to recommend a lower than standard BP treatment target of less than 140/90 mmHg for all patients with nondiabetic CKD. A lower treatment target of less than 130/80 mmHg may delay renal disease progression but only in patients with proteinuria.
No takes yet. Share an insight, caveat, or question.
Schneider et al. (2014) conducted a review in Nondiabetic chronic kidney disease. Lower blood pressure treatment target (<130/80 mmHg) vs. Standard BP treatment target (<140/90 mmHg) was evaluated on Progression of CKD and cardiovascular events. A lower blood pressure treatment target (<130/80 mmHg) may delay renal disease progression only in nondiabetic CKD patients with proteinuria >300 mg/day, with no clear cardiovascular benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: